One in eight women in the US will be diagnosed with breast cancer in her lifetime, yet 20-50% of breast tumor removal procedures are unsuccessful, requiring patients to undergo a second surgical procedure or ionizing radiation therapy. Innoblative is developing Sira™, a saline-assisted Intraoperative Radiofrequency Ablation device, that uses bipolar current to intraoperatively create a controlled zone of ablation. Sira’s unique design and saline microinfusion system allows it to have maximum contact with target tissue and to be powered with existing electrosurgical generators. Innoblative Designs, Inc. has completed a National Science Foundation STTR Phase I grant and is working towards obtaining FDA 510(k) clearance. The team from Northwestern University first participated in VentureWell’s E-Team Program in 2013, and was also the first-place winner at the 2014 BMEidea competition. VentureWell invested in Innoblative Designs, Inc. in 2014.